Korean J Intern Med.
2020 May;35(3):498-513. 10.3904/kjim.2020.105.
Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidence
- Affiliations
-
- 1Division of Cardiology, Hyllym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea
- 2Division of Cardiology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea
- KMID: 2502041
- DOI: http://doi.org/10.3904/kjim.2020.105
Abstract
- Heart failure (HF) is a growing health concern in aging societies worldwide. Sacubitril/valsartan is changing the real-world treatment in the whole spectrum of HF. The beginning was the PARADIGM-HF trial published in 2014, which demonstrated the beneficial effects of inhibiting natriuretic peptide breakdown in combination with hindering the renin-angiotensin system in HF patients with a reduced ejection fraction. Subsequent large-scale randomized trials have evaluated angiotensin receptor-neprilysin inhibitor in HF patients with acute decompensation or with preserved ejection fraction. The post hoc analyses are being conducted as well. This review summarizes the recent evidence of sacubitril/ valsartan regarding patient-centered outcomes, based on randomized controlled trials and their associated studies.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Angiotensin Receptor-Neprilysin Inhibition (ARNI) in Heart Failure
- Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease
- Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction
- Oral pharmacological treatment of congestive heart failure
- Angiotensin Receptor Neprilysin Inhibitors in HFrEF: Is This the First Disease Modifying Therapy Drug Class Leading to a Substantial Reduction in Diuretic Need?
